Defense Company Explodes with 750% Gains

Good Afternoon! 

Hey, everyone. It's Adam from Elite Trade Club. 

Here’s what moved the market today.

Technology

This $9 Trillion Tech Revolution Could Put Your Car to Work

Imagine this: Your car pulls into a garage in the morning and by lunchtime, you’ve earned $40—without lifting a finger.

Now picture that happening every day, all year long, earning you up to $30,000 annually.

This may sound like science fiction, but one breakthrough autonomous technology—backed by Elon Musk—could turn it into reality as soon as next year.

Industry experts are already talking about a $9 trillion market opportunity tied to this project, and one under-the-radar company could be positioned to ride the wave of this tech revolution.

Don’t bet against innovation, and don’t miss this moment.

Click here to discover the details and see why this company could soar.

Markets 📈

The market fought sagged again today, causing U.S. indexes to lose ground across the board. The Russell 2K got hit the hardest, losing over a percent from yesterday.

Market-Moving News 📈

E-Commerce

Alibaba Streamlines Operations with Sale of Intime Retail Unit

Alibaba Group has announced the sale of its Chinese department store unit, Intime, as part of its strategy to refocus on its core e-commerce business. This decision aligns with the company’s broader restructuring efforts, which began last year when it split into six business units and adjusted its leadership team.

The retail giant has been under increasing pressure due to shifting consumer trends and heightened competition from rivals offering steep discounts. Platforms like Pinduoduo and Temu, along with others targeting price-sensitive shoppers, have carved out significant market share, forcing Alibaba to refine its priorities. The challenging economic environment in China has further complicated the retail landscape for both online and offline operations.

Alibaba had acquired Intime in 2017 to expand its physical retail presence but has since decided to scale back its involvement in brick-and-mortar ventures. The company is now looking to offload other retail-related businesses as part of its plan to streamline operations and return its focus to digital commerce.

This move reflects Alibaba’s recognition that offline retail requires substantial resources and attention, which may not align with its current goals. By consolidating efforts, the e-commerce giant aims to better navigate growing competition and the evolving needs of today’s shoppers.

Automobiles

Honda and Nissan Consider Merger to Tackle EV Market Challenges

Honda and Nissan are reportedly exploring the possibility of merging as they face mounting challenges from global electric vehicle (EV) competitors. The two automakers have been strengthening their collaboration over the past year, particularly in EV technology, to keep pace with a rapidly changing industry.

Competition from Chinese EV manufacturers has intensified, forcing legacy brands to reevaluate their strategies. Both companies are contending with shrinking market share in China, where EV adoption has surged, making it a key battleground for automakers worldwide. As they seek to streamline operations, discussions about a joint holding company have emerged, potentially signaling a major shift in the Japanese auto sector.

If realized, the merger would create one of the largest auto alliances globally, rivaling other major industry players. Reports suggest Mitsubishi Motors, where Nissan holds a significant stake, could also be part of the combined entity, further boosting its scale.

The broader auto industry is navigating complex pressures, including rising costs, slowing EV demand in some regions, and uncertainty around government incentives. For Honda and Nissan, deeper collaboration might offer a path to overcome these challenges and strengthen their competitive position in the evolving EV market. Any formal agreement would mark one of the most significant moves in the sector in years.

Healthcare

FDA Delay Slows Launch of Johnson & Johnson's New Cancer Treatment

Johnson & Johnson recently announced that the U.S. FDA has declined to approve its injectable version of the cancer treatment Rybrevant. The decision, tied to manufacturing facility issues identified during a pre-approval inspection, delays the launch of this subcutaneous formulation designed for patients with non-small cell lung cancer (NSCLC) carrying a specific genetic mutation.

The injectable version of the medication was developed in collaboration with Halozyme Therapeutics, which specializes in advanced drug delivery technologies. Importantly, the FDA did not raise concerns regarding the drug’s safety, effectiveness, or formulation. Additionally, no further clinical studies have been requested, indicating the core data supporting the treatment remains solid.

The company has expressed its commitment to addressing the FDA’s concerns and resolving manufacturing-related issues promptly. Bringing this subcutaneous version of Rybrevant to market is expected to offer added convenience for patients compared to existing administration methods.

While the regulatory delay represents a setback, Johnson & Johnson remains focused on advancing the treatment to ensure it becomes available to those who can benefit from it. The company’s efforts highlight its ongoing dedication to improving cancer care and expanding treatment options for patients with specific genetic forms of NSCLC.

Unique IPO Opportunity

This NYSE Stock Could Be Wall Street’s Next Big Play

A $400 million company has just hit the NYSE, and it’s already making noise in a $90 billion market. Backed by some of the biggest names on Wall Street, this firm is shaking up an industry critical to the global economy.

At under $15 a share, this stock offers a rare chance to get in early before the broader market catches on.

With massive potential for growth and a strategic position in its sector, investors are starting to take notice.

Click here to discover the ticker and learn why this stock could dominate the market.

Nukkleus Inc [NUKK] $11.88 (+754.68%)

Nukkleus turned heads today after acquiring a controlling stake in Star 26, a leading supplier for Israeli defense systems.

Portage Biotech Inc [PRTG] $9.04 (+178.15%)

Portage Biotech skyrocketed after sharing a letter of intent to collaborate with Immunova and potentially acquire iOx Therapeutics.

Quantum Computing Inc [QUBT] $16.79 (+51.53%)

Quantum Computing surged yet again, this time in part due to a new contract with NASA.

22nd Century Group Inc [XXII] $4.37 (-22.00%)

22nd Century Group faced further loss today due to its pursuit of a 1-for-135 stock split.

Mama’s Creations Inc [MAMA] $8.25 (-14.95%)

Mama’s Creations suffered setback as investors were not thrilled with the company’s Q3 financial report.

Amentum Holdings Inc [AMTM] $21.51 (-9.66%)

Amentum Holdings revealed strong financials in its latest financial report, but shares fell as the company expects multiple government programs to come to an end.

Technology

A Tech 7.5x Bigger Than the Internet Economy?

A new technology is about to go mainstream – one Google's CEO has praised as more "profound" than fire or electricity.

Get the details here...

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.